3D-Printed Mesoporous Carrier System for Delivery of Poorly Soluble Drugs

Fused deposition modelling (FDM) is the most extensively employed 3D-printing technique used in pharmaceutical applications, and offers fast and facile formulation development of personalized dosage forms.

In the present study, mesoporous materials were incorporated into a thermoplastic filament produced via hot-melt extrusion and used to produce oral dosage forms via FDM. Mesoporous materials are known to be highly effective for the amorphization and stabilization of poorly soluble drugs, and were therefore studied in order to determine their ability to enhance the drug-release properties in 3D-printed tablets. Celecoxib was selected as the model poorly soluble drug, and was loaded into mesoporous silica (MCM-41) or mesoporous magnesium carbonate.

In vitro drug release tests showed that the printed tablets produced up to 3.6 and 1.5 times higher drug concentrations, and up to 4.4 and 1.9 times higher release percentages, compared to the crystalline drug or the corresponding plain drug-loaded mesoporous materials, respectively. This novel approach utilizing drug-loaded mesoporous materials in a printed tablet via FDM shows great promise in achieving personalized oral dosage forms for poorly soluble drugs.

Download the full article here: 3D-Printed Mesoporous Carrier System for Delivery of Poorly Soluble Drugs

Development of a stability indicating high-performance liquid chromatography method for determination of cenobamate: study of basic degradation kinetics

Development and application of control concepts for twin-screw wet granulation in the ConsiGma-25: Part 2 granule size

Advances in Nanocarrier Systems for Overcoming Formulation Challenges of Curcumin: Current Insights

Continue reading here: Katsiotis, C.S.; Åhlén, M.; Strømme, M.; Welch, K. 3D-Printed Mesoporous Carrier System for Delivery of Poorly Soluble Drugs. Pharmaceutics 2021, 13, 1096. https://doi.org/10.3390/pharmaceutics13071096

Materials
Mesoporous magnesium carbonate (MMC) was kindly provided by Disruptive Materials AB (Uppsala, Sweden). Celecoxib was purchased from 3Way Pharm Inc. (Shanghai, China). D-mannitol, ethanol absolute >99.8%, ammonia 28%, and tetraethyl orthosilicate 98% (TEOS) were purchased from VWR International (Stockholm, Sweden). Monobasic sodium phosphate, dibasic sodium phosphate, hexadecyltrimethylammonium bromide (CTAB), and polyvinyl alcohol 4-88 (PVA) were all purchased from Sigma-Aldrich (Stockholm, Sweden).

See also our special on pharmaceutical 3D printing

excipients